Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LAMIVUDINE\TENOFOVIR DISOPROXIL: 143 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
143
Total FAERS Reports
10 (7.0%)
Deaths Reported
9
Hospitalizations
143
As Primary/Secondary Suspect
1
Life-Threatening
1
Disabilities

Active Ingredient: LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE ·

First Report: 20110420 · Latest Report: 20240401

What Are the Most Common LAMIVUDINE\TENOFOVIR DISOPROXIL Side Effects?

#1 Most Reported
Maternal exposure during pregnancy
37 reports (25.9%)
#2 Most Reported
Foetal exposure during pregnancy
32 reports (22.4%)
#3 Most Reported
Abortion spontaneous
30 reports (21.0%)

All LAMIVUDINE\TENOFOVIR DISOPROXIL Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Maternal exposure during pregnancy 37 25.9% 0 0
Foetal exposure during pregnancy 32 22.4% 4 0
Abortion spontaneous 30 21.0% 1 0
Exposure during pregnancy 27 18.9% 2 0
Abortion induced 17 11.9% 0 0
Premature baby 9 6.3% 2 0
Live birth 8 5.6% 0 0
Congenital skin dimples 7 4.9% 0 0
Foetal death 7 4.9% 0 0
Stillbirth 7 4.9% 1 0
Congenital umbilical hernia 6 4.2% 0 0
Premature delivery 6 4.2% 0 0
Virologic failure 6 4.2% 0 0
Anaemia 5 3.5% 1 2
Benign hydatidiform mole 5 3.5% 0 0
Death 5 3.5% 5 1

Who Reports LAMIVUDINE\TENOFOVIR DISOPROXIL Side Effects? Age & Gender Data

Gender: 75.0% female, 25.0% male. Average age: 30.9 years. Most reports from: BR. View detailed demographics →

Is LAMIVUDINE\TENOFOVIR DISOPROXIL Getting Safer? Reports by Year

YearReportsDeathsHosp.
2011 8 0 0
2012 3 0 0
2014 2 0 0
2015 1 0 1
2016 5 0 3
2017 1 0 0
2018 21 5 2
2019 10 0 0
2020 11 0 0
2021 5 0 0
2022 8 0 0
2023 1 0 0
2024 1 0 1

View full timeline →

What Is LAMIVUDINE\TENOFOVIR DISOPROXIL Used For?

IndicationReports
Hiv infection 90
Product used for unknown indication 31
Maternal exposure timing unspecified 10

LAMIVUDINE\TENOFOVIR DISOPROXIL vs Alternatives: Which Is Safer?

LAMIVUDINE\TENOFOVIR DISOPROXIL vs LAMIVUDINE\ZIDOVUDINE LAMIVUDINE\TENOFOVIR DISOPROXIL vs LAMOTRIGINE LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANADELUMAB LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANADELUMAB-FLYO LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANREOTIDE LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANSOPRAZOLE LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANTHANUM LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANTUS LAMIVUDINE\TENOFOVIR DISOPROXIL vs LANTUS SOLOSTAR LAMIVUDINE\TENOFOVIR DISOPROXIL vs LAPATINIB

Official FDA Label for LAMIVUDINE\TENOFOVIR DISOPROXIL

Official prescribing information from the FDA-approved drug label.